Poolbeg currently has a worldwide license for POLB 001 for all uses in humans and is developing an IP portfolio with patent protections covering p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of severe influenza and hypercytokinaemia. Poolbeg is exploring further IP around POLB 001 to cover new disease areas.
Poolbeg already has US and European patents for POLB 001 with claims to the treatment of severe influenza. These patents will offer protection until at least 2037.
Its a bonus when you know whats going on in a company it took me over a year lucky for me the more i found out the more i liked it and the price was falling so i was buying - i did not buy any in may had no funds it went up to 6.90p then back down in june sold out small profit forgot about it down down - looked into it more got funds buying. hold firm this is going places - i took a small profit last week only reasin i got dry on powder
hi moniman - I bought alot more shares then i planned to but its good now its up a bit 6p alot more to go i feel - All theses big deals on the cards great projects even the oral vaccine will be a massive hit very certain over 30p - Whats so good about ORPH now assets worth much?
Geordiechris - Your pumping alot into this i have to say i mostly buy on gut - is the main reason for the fall because of the POLB IPO ? its like me having 4 bank accounts and giving 1 away with the most cash u agree? I do not know enough about this at the moment its hard to fully understand but its nice looking back at the video clips 1 year ago they where so wrong now more the half CF buy price - its a tricky 1 this i will look for now am mostly always right